NCT01460108Unknown4 期
Utility of the AeriSeal System in Patients With Advanced Upper Lobe Predominant Emphysema and Collateral Ventilation Assessed by the Chartis System
LudwLudwig Boltzmann Institute for COPD and Respiratory Epidemiology2 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2011年4月1日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 发起方
- 入组人数
- 10
- 试验地点
- 2
- 主要终点
- Change in Forced Expiratory Volume in one second (FEV1)
研究概览
简要总结
The purpose of this study is to characterize the safety and efficacy of the AeriSeal System in patients with advanced upper lobe predominant emphysema and significant collateral ventilation as determined by the Chartis System.
详细描述
This is an investigator initiated, open-label, uncontrolled study to prospectively characterize the safety and efficacy of the AeriSeal System in patients with advanced upper lobe predominant emphysema found to have significant collateral ventilation using the Chartis System.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Willing and able to provide informed consent and to participate in the study
- •Diagnosis of advanced emphysema (GOLD Stage III or Stage IV disease)
- •Radiologic evidence of non-bullous upper lobe predominant heterogeneous emphysema with at least 2 target sites deemed appropriate for treatment evident by CT imaging
- •DLco between 20 and 60% predicted
- •Positive Collateral Ventilation as determined by the Chartis® System
- •Clinically significant dyspnea (defined as a MRC dyspnea score of 2 or greater at Screening)
- •Failure of standard medical therapy to provide adequate relief of symptoms (defined as regular use of standard medication for more than 1 month prior to Screening; standard medications include at least an inhaled beta agonist and inhaled anticholinergic unless medically contraindicated or prior medical failure)
- •Significant airflow obstruction as demonstrated by Spirometry 15 minutes after administration of bronchodilator with:
- •5% < FEV1 < 50% predicted using the ATS recommended calculation for expected value
- •FEV1/FVC ratio <70%
- •Physiological evidence of hyperinflation with Lung volumes (plethysmographic) of:
- •TLC > 100% predicted using the ATS recommended calculation for expected value
- •RV > 135% predicted using the ATS recommended calculation for expected value
- •Six-Minute Walk Test distance ≥ 150 m
- •Abstinence from inhaled tobacco use for at least 16 weeks prior to the initial Screening visit until the end of the study
- •Female patients are either post-menopausal or surgically sterile. Women with child-bearing potential will not be included in this study
排除标准
- •Alpha-1 antitrypsin serum level of < 80 mg/dL (i.e. < 11 micro mol/L) at Screening
- •Body mass index < 15 kg/m2 or > 35 kg/m
- •Clinically significant asthma, chronic bronchitis or bronchiectasis as determined by the Investigator, or a significant COPD exacerbation within the past 4 months
- •Use of systemic steroids > 20 mg/day or equivalent immunosuppressive agents, heparins, oral anticoagulants (e.g., warfarin, dicumarol; note: antiplatelet drugs including aspirin and clopidogrel are permitted) or investigational medications within 4 weeks of Screening
- •Allergy or sensitivity to medications required to safely perform AeriSeal System treatment under general anesthesia or conscious sedation
- •Participation in an investigational study of a drug, biologic, or device not currently approved for marketing within 30 days prior to the Screening visit
- •Prior lung volume reduction surgery, prior lobectomy or pneumonectomy, prior lung transplantation, prior airway stent placement, prior pleurodesis, or prior endobronchial lung volume reduction therapy of any type
- •Significant co-morbidity that carries prohibitive risks (e.g., HIV/AIDS, cancer) or is associated with less than 2-year expected survival
- •Blood gases and oxygen saturation:
- •SpO2 ≤ 90% on > 4 L/min supplemental O2, at rest
- •PaCO2 ≥ 55mmHg
- •DLCO < 20% or > 60% predicted for patients with heterogeneous emphysema
- •Chest CT scan: Presence of any of the following radiologic abnormalities:
- •Pulmonary nodule on CT scan greater than 1.0 cm in diameter (Does not apply if present for 2 years or more without increase in size or if proven benign by biopsy/PET)
- •Giant Bullous Disease
- •Radiologic picture consistent with active pulmonary infection, e.g., unexplained parenchymal infiltrate
- •Significant interstitial lung disease (based upon investigator judgment)
- •Significant pleural disease (based upon investigator judgment)
- •Any condition that the Investigator believes would interfere with the intent of the study or would make participation not in the best interest of the patient
结局指标
主要结局
Change in Forced Expiratory Volume in one second (FEV1)
时间窗: 12 Weeks
Change from baseline in FEV1 measurement after 12 weeks following completion of therapy.
次要结局
- Change in Forced Expiratory Volume in one second (FEV1).(24 Weeks)
- Change in Forced Vital Capacity (FVC)(12 Weeks and 24 Weeks)
- Change in ratio of Residual Volume to Total Lung Capacity (RV/TLC)(24 Weeks)
- Change in distance walked in six minutes (6MWT)(24 Weeks)
- Change in Medical Research Council Dyspnea (MRCD) score(24 Weeks)
- Change in health related quality of life assessment (St. George's Respiratory Questionnaire)(SGRQ)(24 Weeks)
- Change in Collateral Ventilation(24 Weeks)
- Unanticipated Serious Adverse Device Effects (USADEs)(24 Week)
研究者
Arschang Valipour
Ass. Prof. Department of Respiratory and Critical Care Medicine
LudwLudwig Boltzmann Institute for COPD and Respiratory Epidemiology
研究点 (2)
Loading locations...
相似试验
撤回
3 期
Study of the AeriSeal System Treatment in Patients With Advanced Non-Upper Lobe Predominant Heterogeneous EmphysemaChronic Obstructive Pulmonary Disease (COPD)EmphysemaNCT01908933Aeris Therapeutics
已完成
1 期
AeriSeal System for Lung Volume ReductionChronic Obstructive Pulmonary Disease (COPD)Pulmonary EmphysemaLung DiseasesEmphysemaNCT01051258Aeris Therapeutics55
已完成
2 期
AeriSeal® System for Lung Volume Reduction in Patients With Advanced EmphysemaPulmonary EmphysemaCOPDLung DiseasesNCT01181466Aeris Therapeutics20
终止
2 期
A Continuation Study of the AeriSeal® System Administered at 3 to 4 Sites During a Single Treatment Session for Lung Volume Reduction in Patients With Advanced EmphysemaPulmonary EmphysemaChronic Obstructive Pulmonary Disease(COPD)Lung DiseasesNCT01320566Aeris Therapeutics18
终止
3 期
Study of the AeriSeal System for HyPerInflation Reduction in Emphysema (ASPIRE)Pulmonary EmphysemaNCT01449292Aeris Therapeutics300